MBIO News and Press, Mustang Bio Inc. From 04/18/19

Gainers : Mustang Bio (NASDAQ: MBIO ) +117% . Checkpoint Therapeutics (NASDAQ: CKPT ) +19% . Amyris (NASDAQ: AMRS ) +18% . Uxin (NASDAQ: UXIN ) +17% . Viomi Technology (NASDAQ: VIOT ) +16% . Fortress Biotech (NASDAQ: FBIO ) +15% . Broadwind Energy (NASDAQ: BWEN ) +13% . Libbey (NYSE...

Thinly traded micro cap Mustang Bio ( MBIO +124.1% ) is up on a whopping 420x surge in volume in reaction to positive results from a Phase 1/2 clinical trial evaluating a lentiviral gene therapy in infants with an ultra-rare inherited disorder called XSCID characterized by the absence of...

Mustang Bio ( MBIO ) - As I write this, shares have risen by over 300% after hours after the company announced that the New England Journal of Medicine had published data from St. Jude Children's Research Hospital regarding an early stage gene therapy trial. Specifically, the Phase 1/2 stud...

Mustang Bio (NASDAQ: MBIO ) +212%  after  releasing new data  from a phase 1/2 clinical trial. More news on: Mustang Bio, Inc., Fortress Biotech, Inc., United Rentals, Inc., Stocks on the move, Read more ...

Mustang Bio (NASDAQ: MBIO ) has tripled up, jumping 199% after hours, after releasing new data from a phase 1/2 clinical trial. More news on: Mustang Bio, Inc., Fortress Biotech, Inc., Healthcare stocks news, Stocks on the move Read more ...

Licensing partnership for vector between St. Jude and Mustang Bio announced in Summer, 2018 This Phase 1/2 trial in newly diagnosed infants with XSCID continues to enroll at St. Jude, UCSF Benioff Children’s Hospital and Seattle Children’s Hospital NEW YORK, April 17,...

NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

The following slide deck was published by Mustang Bio, Inc. in conjunction with this Read more ...

Mustang Bio (NASDAQ: MBIO ): FY GAAP EPS of -$1.14. More news on: Mustang Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...